Accessibility Menu
Acrivon Therapeutics logo

Acrivon Therapeutics

(NASDAQ) ACRV

Current Price$1.74
Market Cap$74.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-89%
5 YearN/A
1 Year+35%
1 Month+17%
Acrivon Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 1.752026-07-16
Acrivon Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-14.63%USD 2.052026-07-09
1 month+17.45%USD 1.492026-06-16
3 month-1.69%USD 1.782026-04-17
Year to date-27.39%USD 2.412025-12-31
1 year+34.62%USD 1.302025-07-16
3 year-85.85%USD 12.372023-07-17
Since inception-89.48%USD 16.642022-11-15

Acrivon Therapeutics Financials at a Glance

Market Cap

$74.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$77.27M

EPS (TTM)

-$2.00

P/E Ratio

-0.87

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$1.74

Volume

547,930

Open

$1.89

Previous Close

$1.75

Daily Range

$1.74 - $1.89

52-Week Range

$1.20 - $3.56

Estimated Earnings Date

Aug 12, 2026

ACRV News

Foolcom-Featured.png

Acrivon Posts Narrower Loss in Q2

Motley Fool Markets TeamAug 13, 2025
chalkboard growth concept

2 Breakout Growth Stocks to Buy for the Long Haul

George Budwell, PhDFeb 14, 2023

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Acrivon Therapeutics

Acrivon develops cancer medicines for patients whose tumors match specific biological markers. Its main drug candidates aim to help people with hard-to-treat cancers. The company uses tests to identify which patients are most likely to benefit from its treatments.

Lab Bench to Bedside: What Acrivon Sells

  • ACR-368 (prexasertib): Lead drug candidate for ovarian, endometrial, and bladder cancers; not yet generating revenue.
  • OncoSignature Diagnostics: Tests that identify patients likely to respond to Acrivon’s drugs; no revenue contribution yet.
  • ACR-2316: Early-stage drug targeting cell cycle proteins in solid tumors; pre-commercial, no revenue.
  • ACR-6840: Preclinical drug candidate for cancer; not yet in human trials or generating revenue.
  • AP3 Platform: Technology for discovering and matching drugs to patients; supports internal pipeline, not sold separately.

Growth Spurts and Strategic Moves

  • Advanced ACR-368 into Phase 2 trials for multiple cancers in 2023-2025.
  • Launched Phase 1 trial for ACR-2316 in 2025.
  • Established internal CLIA-certified lab in early 2026, ending partnership with Akoya.
  • Raised $123.8 million in private placement in April 2024.
  • Expanded clinical trial arms and pipeline programs between 2024 and 2026.

Why Acrivon Catches the Eye

Acrivon’s technology measures protein activity in tumors, not just genetic mutations. This approach may help more patients qualify for targeted therapies. The company controls its diagnostic testing in-house, aiming for faster and more reliable trial support.

Five Things You Need to Know

  • Reported $0 revenue in QQ3 2025, unchanged from previous years.
  • Net loss was $-20 million in QQ3 2025, improving 21.7% from QQ3 2024.
  • Cash, cash equivalents, and investments fell 73.8% to $70 million in QQ3 2025.
  • Operating cash flow improved 29.1% to $-12 million in QQ3 2025.
  • No commercial products; all income depends on future drug approvals.

Bottom Line

Acrivon remains focused on developing targeted cancer drugs and companion diagnostics. The company’s future depends on clinical trial progress and securing additional funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

76

CEO

Peter Blume-Jensen, MD, PhD

Website

acrivon.com

Headquarters

Watertown, MA 02472, US

ACRV Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-64.43%

Return on Capital

-73.00%

Return on Assets

-71.65%

Earnings Yield

-1.15%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$74.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

42.80M

Volume

547.93K

Avg. Volume

587.87K

Financials (TTM)

Gross Profit

$228.00K

Operating Income

-$82.35M

EBITDA

-$82.08M

Operating Cash Flow

-$64.67M

Capital Expenditure

-$1.63M

Free Cash Flow

-$66.29M

Cash & ST Invst.

$97.74M

Total Debt

$2.42M

Acrivon Therapeutics Performance Analysis

Acrivon Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Acrivon Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Acrivon Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.4282.6%
20232023-12-31USD -2.7492.4%
20242024-12-31USD -2.38-12.8%
20252025-12-31USD -2.02-15.1%
Acrivon Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-7.8%
Q32025-09-3014.5%
Q42025-12-31-4.3%
Q12026-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$383.00K

-23.2%

Gross Margin

0.00%

N/A

Market Cap

$74.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$998.71K

N/A

Employees

75

N/A

Net Income

-$19.04M

+3.2%

EBITDA

-$18.66M

+3.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$97.74M

-34.7%

Total Debt

$2.42M

-31.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$1.26M

-47.6%

Short Term Debt

$1.15M

+4.3%

Return on Assets

-71.65%

N/A

Return on Invested Capital

-85.10%

N/A

Free Cash Flow

-$20.55M

-4.9%

Operating Cash Flow

-$20.54M

-5.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BMEABiomea Fusion, Inc.
$1.26-2.33%
PMVPPMV Pharmaceuticals, Inc.
$1.30-7.14%
CBUSCibus, Inc.
$1.81-12.98%
TCRXTScan Therapeutics, Inc.
$0.90-2.65%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$15.60-0.00%
ATAIAtaiBeckley
$7.15+0.33%
NOKNokia
$10.38-0.08%
ONDSOndas
$6.65-0.06%

Questions About ACRV

What is the current price of Acrivon Therapeutics?

Acrivon Therapeutics is trading at $1.75 per share.

What is the 52-week range for Acrivon Therapeutics?

Over the past 52 weeks, Acrivon Therapeutics has traded between $1.20 and $3.56.

How much debt does Acrivon Therapeutics have?

As of the most recent reporting period, Acrivon Therapeutics reported total debt of $2.42M.

How much cash does Acrivon Therapeutics have on hand?

Acrivon Therapeutics reported $34.06M in cash and cash equivalents in its most recent financial results.

What is Acrivon Therapeutics’s dividend yield?

Acrivon Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services